[go: up one dir, main page]

WO1999040898A3 - Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect - Google Patents

Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect Download PDF

Info

Publication number
WO1999040898A3
WO1999040898A3 PCT/CA1999/000095 CA9900095W WO9940898A3 WO 1999040898 A3 WO1999040898 A3 WO 1999040898A3 CA 9900095 W CA9900095 W CA 9900095W WO 9940898 A3 WO9940898 A3 WO 9940898A3
Authority
WO
WIPO (PCT)
Prior art keywords
action
rapid onset
drug formulations
therapeutic effect
sublingual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/000095
Other languages
French (fr)
Other versions
WO1999040898A2 (en
Inventor
Rene Kerouac
Georges Bruttmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRAPHARM Inc
Original Assignee
CENTRAPHARM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2243983 external-priority patent/CA2243983A1/en
Application filed by CENTRAPHARM Inc filed Critical CENTRAPHARM Inc
Priority to AU24062/99A priority Critical patent/AU2406299A/en
Publication of WO1999040898A2 publication Critical patent/WO1999040898A2/en
Publication of WO1999040898A3 publication Critical patent/WO1999040898A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to sublingual drug formulations containing active ingredients in dosages equal to or near standard oral dosages. A portion of sublingual form is sublingually absorbed and the remaining portion of the same is absorbed mainly by the enteral route. These formulations have a more rapid onset of action than and a termination of action similar to that of oral forms. As a result, the pharmacological effect is prolonged (almost doubled). Overall total bioavailability is the same as for oral forms. Formulations useful in the treatment of allergy and asthma are disclosed. They comprise at least one of the following: a β2-mimetic, a corticosteroid, an anti-H1 histamine, an anti-cholinergic, a xanthine derivative, a non-steroid anti-inflammatory agent, an anti-leukotriene and a mast cell stabilizer.
PCT/CA1999/000095 1998-02-12 1999-02-11 Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect Ceased WO1999040898A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24062/99A AU2406299A (en) 1998-02-12 1999-02-11 Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7454898P 1998-02-12 1998-02-12
US60/074,548 1998-02-12
CA2,243,983 1998-09-17
CA 2243983 CA2243983A1 (en) 1998-02-12 1998-09-17 Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect

Publications (2)

Publication Number Publication Date
WO1999040898A2 WO1999040898A2 (en) 1999-08-19
WO1999040898A3 true WO1999040898A3 (en) 1999-11-04

Family

ID=25680401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000095 Ceased WO1999040898A2 (en) 1998-02-12 1999-02-11 Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect

Country Status (2)

Country Link
AU (1) AU2406299A (en)
WO (1) WO1999040898A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355406A (en) * 1999-10-23 2001-04-25 Alkaloid Ad A sub-lingual dosage form comprising a morphine salt
ITRM20030288A1 (en) * 2003-06-10 2004-12-11 Valerio Cioli SUBLINGUAL ADMINISTRATION OF NON STEROID INFLAMMATORY (NSAID)
MXPA06012088A (en) * 2004-04-22 2007-08-14 Duocort Ab Pharmaceutical compositions for acute glucocorticoid therapy.
EP1845979A4 (en) * 2005-01-19 2009-11-11 Neurohealing Pharmaceuticals I Methods and compositions for decreasing saliva production
EP1810678A1 (en) 2006-01-19 2007-07-25 Holger Lars Hermann Use of morphine and naloxone for drug substitution
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
CA2687124A1 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
CA2687118A1 (en) 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
WO2007136845A2 (en) 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. Low-dose doxepin for treatment of sleep disorders in elderly patients
ITMI20061117A1 (en) * 2006-06-09 2007-12-10 Michele Bonanomi A PHARMACEUTICAL COMPOSITION FOR THE SUBLINGUAL ADMINISTRATION OF VACCINI METHOD FOR ITS PREPARATION AND USES
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
WO2008128115A2 (en) 2007-04-13 2008-10-23 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
FR2926722B1 (en) * 2008-01-25 2010-09-03 Substipharm Dev APPROPRIATE PHARMACEUTICAL FORMULATION FOR THE PREPARATION OF ORODISPERSIBLE PRELOISOLONE TABLETS
WO2011101734A2 (en) 2010-02-22 2011-08-25 Lupin Limited Taste-masked powder for suspension compositions of methylprednisolone
KR20240011239A (en) 2014-10-29 2024-01-25 삼손 클리니컬 피티와이 엘티디 Detection And Treatment Of Excessive Hair Shedding
US20170216220A1 (en) * 2016-02-03 2017-08-03 Intelgenx Corp. Loxapine film oral dosage form
US9949934B1 (en) 2016-10-20 2018-04-24 Intelgenx Corp. Device and method of treating conditions associated with neuroinflammation
CA3069336A1 (en) * 2017-07-12 2019-01-17 Samson Clinical Pty Ltd Promoting hair growth and treatment of hair loss or excessive hair shedding
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
EP0306422A1 (en) * 1987-09-02 1989-03-08 Medibrevex Sa Galenical forms of 2-beta-mimetics for perlingual and sublingual administration
EP0311540A1 (en) * 1987-10-08 1989-04-12 Medibrevex Sa Galenical forms of corticoids for per- and sublingual administration, and their preparation process
FR2640138A1 (en) * 1988-12-13 1990-06-15 Medibrevex Process for obtaining dosage forms based on active pharmaceutical compounds for per- and sublingual administration
WO1998002187A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
EP0306422A1 (en) * 1987-09-02 1989-03-08 Medibrevex Sa Galenical forms of 2-beta-mimetics for perlingual and sublingual administration
EP0311540A1 (en) * 1987-10-08 1989-04-12 Medibrevex Sa Galenical forms of corticoids for per- and sublingual administration, and their preparation process
FR2640138A1 (en) * 1988-12-13 1990-06-15 Medibrevex Process for obtaining dosage forms based on active pharmaceutical compounds for per- and sublingual administration
WO1998002187A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug

Also Published As

Publication number Publication date
AU2406299A (en) 1999-08-30
WO1999040898A2 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
WO1999040898A3 (en) Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
CA2457361A1 (en) Opioid agonist formulations with releasable and sequestered antagonist
WO2000003753A3 (en) Microdisperse drug delivery systems
DK0904055T3 (en) Non-polar buccal spray or capsule
ITMI961152A0 (en) THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ACTIVE INGREDIENT, ESTROGEN OR PROGESTIN OR MIXTURES THEREOF
CA2370565A1 (en) Dermally applicable vitamin d-containing pharmaceutical compositions
WO2004043428A3 (en) Buccal, polar and non-polar spray or capsule containing drugs for treating pain
AU1434000A (en) Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption
WO2004035021A3 (en) Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
EP1419803A3 (en) Pharmaceutical composition for topical administration comprising an antiviral substance and a glucocorticoid
WO2004019912A3 (en) Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer
WO2003063800A8 (en) 8-heteroaryl xanthine adenosine a2b receptor antagonists
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
CA2319201A1 (en) Celecoxib compositions
NO20045140L (en) Mixtures and Methods for Transmucosal Drug Delivery and Cryoprotection
WO2004019911A3 (en) Buccal, polar or non-polar spray or capsule containing drugs for treating endocrine disorders
ATE329608T1 (en) FORMULATIONS OF COPOLYMER 1 (GLATIRAMER ACETATE) FOR ORAL, NASAL AND PULMONARY ADMINISTRATION
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
CA2312840A1 (en) The use of polyols in combating yeast infection and polyol preparations for said use
AU2108500A (en) Galenic formulation containing biotin
EP0190891A3 (en) Novel amino acid derivatives
WO1999012545A3 (en) Medicaments containing acyclovir
AU2003215680A1 (en) New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives
WO2001026621A3 (en) Orally distintegrating composition comprising mirtazapine
JP2002503687A5 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA